Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other Operating Expenses (2022 - 2025)

Historic Other Operating Expenses for Verrica Pharmaceuticals (VRCA) over the last 4 years, with Q3 2025 value amounting to $1.1 million.

  • Verrica Pharmaceuticals' Other Operating Expenses rose 15494.25% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year decrease of 4419.17%. This contributed to the annual value of -$100000.0 for FY2024, which is 9605.83% up from last year.
  • As of Q3 2025, Verrica Pharmaceuticals' Other Operating Expenses stood at $1.1 million, which was up 15494.25% from $494000.0 recorded in Q2 2025.
  • In the past 5 years, Verrica Pharmaceuticals' Other Operating Expenses registered a high of $2.8 million during Q4 2023, and its lowest value of $62000.0 during Q4 2022.
  • In the last 4 years, Verrica Pharmaceuticals' Other Operating Expenses had a median value of $435000.0 in 2024 and averaged $591400.0.
  • Within the past 5 years, the most significant YoY rise in Verrica Pharmaceuticals' Other Operating Expenses was 443064.52% (2023), while the steepest drop was 7553.96% (2023).
  • Verrica Pharmaceuticals' Other Operating Expenses (Quarter) stood at $62000.0 in 2022, then surged by 4430.65% to $2.8 million in 2023, then plummeted by 74.8% to $708000.0 in 2024, then surged by 56.64% to $1.1 million in 2025.
  • Its Other Operating Expenses stands at $1.1 million for Q3 2025, versus $494000.0 for Q2 2025 and $437000.0 for Q1 2025.